CFC MDI marketing by firms pursuing CFC-free alternatives should be allowed, Glaxo contends.
Executive Summary
CFC MDI MARKETING BY COMPANIES PURSUING CFC-FREE PRODUCTS SHOULD BE ALLOWED, Glaxo maintained in comments on FDA's proposed rule on the phase-out of chlorofluorocarbon-containing metered dose inhalers. "FDA should not ban a CFC product when its manufacturer is actively pursuing approval of a CFC-free alternative product containing the same active moiety as the CFC product," Glaxo Wellcome said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth